Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Jun;206(6):1593-1603.
doi: 10.1111/bjh.20129. Epub 2025 May 19.

Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline

Sridhar Chaganti  1 , Christopher P Fox  2 , Bernard D Maybury  1 , Cathy Burton  3 , Sally F Barrington  4 , Timothy Illidge  5 , Nagesh Kalakonda  6 , Toby A Eyre  7 , Pam McKay  8 , Andrea Kuhnl  9 , Kate Cwynarski  10 , Andrew J Davies  11 ; BSH Committee
Affiliations
Practice Guideline

Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline

Sridhar Chaganti et al. Br J Haematol. 2025 Jun.

Abstract

Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.

Keywords: B‐cell lymphoma; antibody therapy; cellular therapies; immunotherapies; non‐Hodgkin lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Fox CP, Chaganti S, McIlroy G, Barrington SF, Burton C, Cwynarski K, et al. The management of newly diagnosed large B‐cell lymphoma: a British Society for Haematology guideline. Br J Haematol. 2024;204(4):1178–1192.
    1. Campo E, Jaffe ES, Cook JR, Quintanilla‐Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253.
    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748.
    1. Sehn LH, Gilles S. Diffuse large B‐cell lymphoma. N Engl J Med. 2021;384(9):842–858.
    1. Larouche JF, Berger F, Chassagne‐Clément C, Ffrench M, Callet‐Bauchu E, Sebban C, et al. Lymphoma recurrence 5 years or later following diffuse large B‐cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094–2100.

Publication types

MeSH terms

Substances

LinkOut - more resources